Janet Anciro, MD
Internal Medicine · Melbourne, FLNPI 1578538278
Payments from drug & device makers
Across 361 payments — averaging $19.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- AstraZeneca$1K
- Lilly USA, LLC$638
- Boehringer Ingelheim$508
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$455
- AbbVie$384
- plus $2K from 22 others
What the payments were for
- Food & beverage$6,841100%
- Education$290%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 94 | $1,595 |
| AstraZeneca | 69 | $1,302 |
| Lilly USA, LLC | 29 | $638 |
| Boehringer Ingelheim | 27 | $508 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 31 | $455 |
| AbbVie(2 entities) | 19 | $384 |
| Amgen | 19 | $363 |
| Exact Sciences | 13 | $326 |
| Sanofi-aventis U.S. LLC | 12 | $248 |
| Pfizer | 11 | $225 |
| Abbott | 8 | $161 |
| Vanda Pharmaceuticals Inc. | 5 | $108 |
| Novocure Inc. | 1 | $85 |
| Novartis | 3 | $64 |
| Phathom Pharmaceuticals, Inc. | 1 | $55 |
| Merck | 3 | $50 |
| GSK | 2 | $47 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $43 |
| Amarin Pharma, Inc. | 2 | $42 |
| Endo Pharmaceuticals Inc. | 2 | $36 |
| Alnylam Pharmaceuticals Inc. | 1 | $28 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $24 |
| Eisai Inc. | 1 | $16 |
| Biohaven Pharmaceuticals, Inc. | 1 | $15 |
| Dexcom, Inc. | 1 | $14 |
| Grifols USA, LLC | 1 | $14 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
| Idorsia Pharmaceuticals US Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,870 in reported general payments places this provider in the 90th percentile of 8,530 internal medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| HetliozTasimelteon | 13 | $330,038 |
| OzempicSemaglutide | 85 | $128,901 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 54 | $92,348 |
| MounjaroTirzepatide | 44 | $67,265 |
| JardianceEmpagliflozin | 46 | $54,486 |
| RybelsusSemaglutide | 29 | $45,762 |
| EliquisApixaban | 36 | $45,073 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 32 | $29,334 |
| Tresiba Flextouch U-200Insulin Degludec | 25 | $25,826 |
| FarxigaDapagliflozin Propanediol | 16 | $23,559 |
| TrulicityDulaglutide | 13 | $21,874 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 23 | $21,706 |
| XareltoRivaroxaban | 25 | $18,454 |
| Repatha SureclickEvolocumab | 22 | $17,969 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 25 | $12,597 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Vanda Pharmaceuticals Inc.Hetlioz | $108 | $330,03813 claims |
| Novo NordiskOzempic, Rybelsus | $1,595 | $174,663114 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $248 | $92,34854 claims |
| Lilly USA, LLCMounjaro, Trulicity | $638 | $89,14057 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat | $508 | $67,08271 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $1,302 | $45,26439 claims |
| PfizerEliquis | $225 | $45,07336 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $47 | $34,16444 claims |
| MerckDulera | $50 | $3,79611 claims |
| AbbVieSynthroid | $384 | $2,08733 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,530 internal medicine providers in Florida.
Other internal medicine in Melbourne
- Yaneicy Gonzalez RojasCoral Gables$93.5M
- Juan Carlos RondonHollywood$66.8M
- Jaynier MoyaPembroke Pines$45.4M
- Mark KutnerMiami$35.7M
- Gilberto JimenezHialeah$35.6M
- Mira BaronWest Palm Beach$29.6M
- William SanchezHialeah$28.9M
- Nelia Sanchez-CrespoHollywood$28.8M
- Kwabena AyesuOrlando$27.6M
- Michael DeverWindermere$24M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.